Tetsu Shinkai

4.1k total citations
146 papers, 3.2k citations indexed

About

Tetsu Shinkai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Tetsu Shinkai has authored 146 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 82 papers in Pulmonary and Respiratory Medicine and 36 papers in Molecular Biology. Recurrent topics in Tetsu Shinkai's work include Lung Cancer Treatments and Mutations (57 papers), Lung Cancer Research Studies (56 papers) and Lung Cancer Diagnosis and Treatment (30 papers). Tetsu Shinkai is often cited by papers focused on Lung Cancer Treatments and Mutations (57 papers), Lung Cancer Research Studies (56 papers) and Lung Cancer Diagnosis and Treatment (30 papers). Tetsu Shinkai collaborates with scholars based in Japan, United States and United Kingdom. Tetsu Shinkai's co-authors include Nagahiro Saijo, Tomohide Tamura, Kenji Eguchi, Yasutsuna Sasaki, Yuichiro Ohe, Kazuhiko Nakagawa, Keigo Tominaga, Akira Kojima, Koji Takeda and Yukío Shimosato and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Tetsu Shinkai

141 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tetsu Shinkai Japan	29	2.0k	1.8k	782	401	338	146	3.2k
Elaine M. Rankin United Kingdom	28	2.1k 1.0×	1.5k 0.9×	731 0.9×	350 0.9×	802 2.4×	60	3.5k
Albert Abad Spain	28	2.5k 1.2×	1.6k 0.9×	1.2k 1.5×	489 1.2×	216 0.6×	84	4.2k
Panos Fidias United States	25	1.7k 0.8×	1.8k 1.1×	925 1.2×	210 0.5×	170 0.5×	58	3.0k
Giacomo Cartenì Italy	27	1.7k 0.9×	1.4k 0.8×	648 0.8×	864 2.2×	282 0.8×	110	3.2k
Charles Butts Canada	32	3.5k 1.7×	2.6k 1.5×	1.1k 1.4×	439 1.1×	306 0.9×	96	5.3k
Ralph Levitt United States	27	2.1k 1.0×	892 0.5×	670 0.9×	682 1.7×	424 1.3×	67	3.6k
Ian Quirt Canada	31	1.5k 0.8×	839 0.5×	849 1.1×	248 0.6×	261 0.8×	80	2.8k
Jens Benn Sørensen Denmark	35	1.9k 0.9×	2.4k 1.4×	932 1.2×	333 0.8×	320 0.9×	143	4.0k
Wallace Akerley United States	36	2.7k 1.3×	3.1k 1.8×	1.1k 1.4×	515 1.3×	438 1.3×	156	5.2k
Luigi Manzione Italy	29	2.4k 1.2×	1.3k 0.7×	386 0.5×	637 1.6×	186 0.6×	88	3.4k

Countries citing papers authored by Tetsu Shinkai

Since Specialization

Citations

This map shows the geographic impact of Tetsu Shinkai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tetsu Shinkai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tetsu Shinkai more than expected).

Fields of papers citing papers by Tetsu Shinkai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tetsu Shinkai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tetsu Shinkai. The network helps show where Tetsu Shinkai may publish in the future.

Co-authorship network of co-authors of Tetsu Shinkai

This figure shows the co-authorship network connecting the top 25 collaborators of Tetsu Shinkai. A scholar is included among the top collaborators of Tetsu Shinkai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tetsu Shinkai. Tetsu Shinkai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shimomura, Akihiko, Toshimi Takano, Shunji Takahashi, et al.. (2022). Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer. Clinical Pharmacology & Therapeutics. 113(1). 160–169. 11 indexed citations

Kozuki, Toshiyuki, Naoyuki Nogami, Osamu Hataji, et al.. (2020). Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational Lung Cancer Research. 9(3). 459–470. 4 indexed citations

Kozuki, Toshiyuki, Naoyuki Nogami, Shunichiro Iwasawa, et al.. (2016). Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015. BMC Cancer. 16(1). 306–306. 6 indexed citations

Kubota, Kaoru, Y. Ichinose, Giorgio V. Scagliotti, et al.. (2014). Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Annals of Oncology. 25(2). 529–536. 20 indexed citations

Tanaka, Nobumichi, Keisuke Fujimoto, Tetsu Shinkai, et al.. (2011). Bone Scan Can Be Spared in Asymptomatic Prostate Cancer Patients with PSA of <=20 ng/ml and Gleason Score of <=6 at the Initial Stage of Diagnosis. Japanese Journal of Clinical Oncology. 41(10). 1209–1213. 28 indexed citations

Kawahara, Masaaki, Harue Tada, Akihiro Tokoro, et al.. (2011). Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01). BMC Cancer. 11(1). 356–356. 10 indexed citations

Teramoto, Norihiro, et al.. (2009). Re‐classification of pTNM staging for lung cancer: Single‐institution report at a Japanese comprehensive cancer hospital. Pathology International. 59(6). 376–381. 2 indexed citations

Sekine, Ikuo, Y. Ichinose, Yutaka Nishiwaki, et al.. (2009). Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Annals of Oncology. 20(9). 1483–1488. 26 indexed citations

Sawada, Shigeki, Eisaku Komori, Naoyuki Nogami, et al.. (2009). Evaluation of lesions corresponding to ground-glass opacities that were resected after computed tomography follow-up examination. Lung Cancer. 65(2). 176–179. 45 indexed citations

10.

Sekine, Ikuo, Yukito Ichinose, Yutaka Nishiwaki, et al.. (2007). B3-01: A randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with previously treated advanced non-small-cell lung cancer. Journal of Thoracic Oncology. 2(8). S339–S340. 3 indexed citations

11.

Takigawa, Nagio, Katsuyuki Kiura, Yoshihiko Segawa, et al.. (2006). Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. British Journal of Cancer. 95(9). 1142–1144. 20 indexed citations

12.

Segawa, Yoshihiko, Katsuyuki Hotta, Shigeki Umemura, et al.. (2006). Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. Cancer. 107(8). 1866–1872. 2 indexed citations

13.

Ohe, Yuichiro, Kazuto Nishio, Hideo Kunitoh, et al.. (1998). Factors that Influence the Eligibility of Cases for Inclusion in Clinical Trials. Japanese Journal of Clinical Oncology. 28(3). 214–221. 2 indexed citations

14.

Saijo, Nagahiro, Kazuto Nishio, Naohiro Kubota, et al.. (1994). 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer Chemotherapy and Pharmacology. 34(S1). S112–S117. 11 indexed citations

15.

Fukutani, Miki, Kinuko Tajima, Yuka Tanaka, et al.. (1992). Feasibility Study on Quality-of-life Questionnaires for Patients with Advanced Lung Cancer. Japanese Journal of Clinical Oncology. 22(3). 185–93. 14 indexed citations

16.

Shinkai, Tetsu, Kenji Eguchi, Yasutsuna Sasaki, et al.. (1991). A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. European Journal of Cancer and Clinical Oncology. 27(5). 571–575. 24 indexed citations

17.

Kojima, Akira, Tatsuro Ikeuchi, Motoko Inomata, et al.. (1991). Y/6 chromosome translocation in a male with triple primary cancers involving the breast. Journal of Cancer Research and Clinical Oncology. 117(5). 479–483. 2 indexed citations

18.

Eguchi, Kenji, Tetsu Shinkai, Yasutsuna Sasaki, et al.. (1990). Subcutaneous Administration of Recombinant Human Granulocyte Colony‐stimulating Factor (KRN8601) in Intensive Chemotherapy for Patients with Advanced Lung Cancer. Japanese Journal of Cancer Research. 81(11). 1168–1174. 21 indexed citations

19.

Eguchi, K., N. Saijo, Tetsu Shinkai, et al.. (1987). [Recent status of the diagnosis and treatment of bone metastasis in patients with advanced lung cancer].. PubMed. 14(5 Pt 2). 1696–703. 3 indexed citations

20.

Kanzawa, Fumihiko, Anne W. Hamburger, Yasutsuna Sasaki, et al.. (1987). Human Tumor Clonogenic Assay for Carcinoma of the Lung. Oncology. 44(3). 150–155. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact